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Differential In Vitro Immortalization Capacity of Eleven, Probable
High-Risk Human Papillomavirus Types
Denise M. Schütze,a Peter J. F. Snijders,a Leontien Bosch,a Duco Kramer,a,b Chris J. L. M. Meijer,a Renske D. M. Steenbergena
Department of Pathology, Unit of Molecular Pathology, VU University Medical Center, Amsterdam, The Netherlandsa; Center for Blistering Diseases, Department of
Dermatology, University Medical Center Groningen, Groningen, The Netherlandsb
Epidemiological studies identified 12 high-risk HPV (hrHPV) types and 8 probable/possible hrHPV types that display different
cancer risks. Functional studies on transforming properties of hrHPV are mainly limited to HPV16 and -18, which induce im-
mortalization of human foreskin keratinocytes (HFKs) by successive bypass of two proliferative life span barriers, senescence
and crisis. Here, we systematically compared the in vitro immortalization capacities, as well as influences on p53, pRb, hTERT,
growth behavior, and differentiation capacity, of nine hrHPV types (HPV16, -18, -31, -33, -35, -45, -51, -52, and -59), and two
probable hrHPV types (HPV66 and -70). By retroviral transduction, the respective E6/E7 coding sequences were expressed in
HFKs from two or three independent donors. Reduced p53 levels and low-level hTERT expression in early-passage cells, as seen
in HPV16-, -31-, -33-, and -35-, and to a lesser extent HPV18-transduced HFKs, was associated with continuous growth and an
increased immortalization capacity. Less frequent immortalization by HPV45 and -51 and immortalization by HPV66 and -70
was preceded by an intervening period of strongly reduced growth (crisis) without prior increase in hTERT expression. Immor-
talization by HPV59 was also preceded by a period crisis, despite the onset of low hTERT expression at early passage. HPV52
triggered an extended life span but failed to induce immortality. Variations in p53 and pRb levels were not correlated with differ-
ences in alternative E6/E7 mRNA splicing in all hrHPV-transduced HFKs. On collagen rafts, transductants showed disturbed
differentiation reminiscent of precancerous lesions. In conclusion, in vitro oncogenic capacities differ between the established
hrHPV types, and both some established and probable hrHPV types display weak or moderate immortalization potential.
Cervical cancer, the thirdmost common cancer among womenworldwide, is caused by a persistent infection with certain
types of human papillomavirus (HPV) (1, 2). Most HPV infec-
tions are transient and are cleared within 1 to 2 years. However, a
fraction of infections eventually give rise to either squamous cell
carcinoma (SCC) or adenocarcinoma (AdCA) of the cervix. SCCs
develop from so-called cervical intraepithelial neoplasia (CIN)
precursor lesions. Low-grade CIN lesions (CIN1) mostly reflect a
productive infection in which viral replication and virion produc-
tion are linked to the differentiation program of the epithelium.
High-grade CIN lesions (CIN2/3) mainly represent transforming
infections and are characterized by deregulated expression of the
early viral E6 and E7 genes in the proliferating basal cells of the
epithelium (3, 4).
HPV types belonging to the alpha () genus can infect the
cervical mucosa (5) and are classified into low-risk (lrHPV) and
high-risk (hrHPV) HPV based on their association with malig-
nancy (6). Infections with lrHPV types, e.g., HPV type 6 (HPV6)
andHPV11, are associatedwith benignwarts or low-grade lesions,
whereas infections with hrHPV can give rise to high-grade CIN
lesions and carcinoma. According to epidemiological and biolog-
ical criteria, 12 HPV types have now been consistently classified as
high risk (i.e.,HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58,
and -59 [International Agency for Research on Cancer {IARC}
group 1]). Another 8 types have been classified as probable or
possible high risk (i.e., HPV26, -53, -66, -67, -68, -70, -73, and -82
[IARC group 2A/B]) (7). Due to the rare detection of the latter
group of types in cervical cancers, there is very limited or no evi-
dence of their carcinogenicity.
Longitudinal studies have revealed that even established
hrHPV types confer different risks of CIN3 or cancer. Infections
with the hrHPV types 16, 18, 31, 33, 35, 45, 52, and 58 comprise
the highest long-term (5-year) risk of CIN3 or higher lesions,
whereas most of the other hrHPV types present an almost negli-
gible long-term risk (8–10). Furthermore, a large, randomized,
controlled prospective trial conducted in the Netherlands has re-
vealed that among hrHPV-positive women with normal cytology
or borderline tomoderate dyskaryosis, those infectedwith hrHPV
types 16, 18, 31, and 33 have an increased 18-month risk of CIN3
or cancer (8). Apart from type-specific differences in viral persis-
tence (9), these and other data also point to the existence of dif-
ferent oncogenic properties of the various high-risk types.
Although some non-HPV16 and -18 types recently received
some attention (11–14), functional studies on transforming prop-
erties of hrHPV aremainly limited toHPV16 andHPV18.We and
others have previously demonstrated that HPV16 andHPV18 can
induce immortalization of primary human foreskin keratinocytes
(HFKs) by successive bypass of two proliferative life span barriers,
i.e., senescence and crisis (reviewed in reference 15). Bypass of
senescence relies primarily on the expression of the virus-encoded
oncoproteins E6 and E7, which act synergistically by deregulating
apoptosis and the cell cycle of the infected cell, respectively. E6
inactivates the tumor suppressor p53 gene, resulting in loss of
p53-mediated apoptosis, as well as a number of other targets, such
as BAK, Dlg,Magi-1, and hScrib (16). The retinoblastoma protein
(pRb) and family members (e.g., p107 and p130) are inactivated
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by the viral oncogene E7 (reviewed in reference 17). Upon bypass
of senescence, cells begin an extended though still limited life
span. Subsequent immortalization may depend on the HPV type
and/or, in part, also upon culture conditions and may be infre-
quent and preceded by an evident second proliferative life span
barrier, crisis, resulting from extremely eroded chromosome ends
(18, 19). In most instances, immortalization is characterized by
activation of the telomere-lengthening enzyme telomerase, result-
ing from upregulated expression of the telomerase catalytic sub-
unit hTERT (20, 21).
E6 and E7 are expressed from a bicistronic mRNA and, in the
case of hrHPV, are subject to alternative splicing, leading to sev-
eral truncated versions of E6 named E6*I to E6*IV and E7 (22–
24). Whether splicing of E6 enhances the translation efficiency of
E7 is still controversial.Whereas in some studies an increase in the
efficiency of E7 translation was reported (25–27), in other studies,
E7 is translated equally efficiently from spliced and unspliced
transcripts (28, 29). Nevertheless, E6* has been found to function
independently of E6 in the transformation process (30, 31).
To date, a limited number of comparative in vitro studies on
the oncogenic capacity of high-risk and probable high-risk HPV
types have been described, most of which lack a comprehensive
comparison of multiple molecular and growth characteristics in
combination with genetic background dependency.
This study aimed to analyze the in vitro immortalization capac-
ities of the E6/E7 genes of 11 (probable) hrHPV types. HFKs iso-
lated from independent donors were transduced with the E6/E7
open reading frame of hrHPV16, -18, -31, -33, -35, -45, -51, -52,
and -59 and the probable hrHPV types 66 and 70. Low-risk
HPV11 and an empty vector were included as negative controls.
We closely monitored stably transduced HFKs for their p53, pRb,
and p16INK4A status; their growth behavior in culture; and immor-
talization by analyzing hTERT expression and telomerase activa-
tion and their differentiation potentials on organotypic raft cul-
tures.
MATERIALS AND METHODS
Generation of retroviral constructs. The E6 and E7 open reading frames
of HPV11, -16, -18, -31, -33, -35, -45, -51, -52, -59, -66, and -70 were
amplified using Phusion High-Fidelity DNA polymerase (Finnzymes,
Espoo, Finland). PCR products containing an XhoI and a NotI restriction
site and a Kozak sequence were first cloned into a pCR-Blunt II-TOPO
vector (Invitrogen/Life Technologies, Carlsbad, CA). The E6/E7 frag-
ments were subsequently inserted into the XhoI and NotI restriction sites
of the retroviral vector LZRS-MS-IRES-NEO/pBR (LZRS) (kindly pro-
vided by J. Collard, NKI, Amsterdam, The Netherlands). All intermediate
HPVE6/E7 pCR-Blunt II-Topo and LZRS constructs generatedwere con-
firmed byDNA sequence analysis and compared to theGenBank database
(http://www.ncbi.nlm.nih.gov/GenBank/index.html). Sequencing analy-
sis of the E6E7 genes revealed no mutations for HPV11 (accession
no. FR872717), HPV16 (accession no. K02718), HPV18 (accession no.
EF202155), HPV31 (accession no. J04353), HPV33 (accession no.
M12732), HPV35 (accession no. M74117), and HPV45 (accession
no. X74479). In HPV51 E7 (accession no.M62877), onemutation (S66L)
and two silentmutations (T79T and L91L) were observed. HPV52 (acces-
sion no. X74481) contains one silentmutation (L83L), onemutation in E6
(K93R), and two silent mutations in E7 (L67L and Q83Q), and HPV59
(accession no. X77858) has two silent mutations (S89S and D116D) in E6
and threemutations in E7 (L19G, L20F, andH95R). Two silentmutations
(L43L and Thr146Thr) were observed in HPV66 E6 (accession no.
M75123) and one mutation (N100D) in HPV70 E6 (accession no.
U21941). HPV E6/E7 containing LZRS constructs were transfected into
the 293T-based Phoenix amphotropic packaging cell line, and after selec-
tion with puromycin, recombinant helper retroviruses were retrieved as
described previously (32).
Retroviral transduction and cell culture.All cells were grown at 37°C
and 5%CO2. HFKs were isolated from the foreskins of three independent
donors as described previously (21). After two initial passages, HFKs were
transduced with amphotropic retroviruses expressing the HPV E6/E7 on-
cogenes using 15 g/ml Polybrene (Life Technologies, Breda, The Neth-
erlands). Geneticin selection (80 g/ml; Life Technologies) was per-
formed 48 h after transduction. Primary HFKs and transductants were
cultured in defined keratinocyte serum-free medium (SFM) (Life Tech-
nologies) containing 5 ng/ml epidermal growth factor (EGF) and 50
ng/ml bovine pituitary extract, 100 U/ml penicillin, 100 g/ml strepto-
mycin, and 2 mmol/liter L-glutamine (Life Technologies) and grown to
subconfluence until passage. The splitting dates and dilutions were re-
corded to generate growth curves and proliferation characteristics. Expo-
nentially growing cells were harvested every few passages, and the cell
pellets were stored at80°C. DNAwas isolated by proteinase K digestion
followed by UltraPure Phenol:Chloroform:Isoamyl Alcohol (Life Tech-
nologies) extraction (33). Total RNA was isolated using TRIzol Reagent
(Life Technologies) according to the manufacturer’s instructions.
SiHa cells were obtained from the American Type Culture Collection
(Manassas, VA) and were grown in Dulbecco’s modified Eagle medium
(DMEM) (Life Technologies) supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 g/ml streptomycin, and 2 mmol/liter L-glu-
tamine (all from Life Technologies).
HPV DNA and RNA analysis. Throughout culturing, DNA was iso-
lated from all transductants to verify the presence of the correct HPV type
usingHPV type-specific E7 primers. Using a quantitative PCR (qPCR) for
the viral backbone targeting the LZRS sequence and beta-globin as a ref-
erence, the quantities of ectopic DNA were measured.
For E6 and E7 expression analysis, 500 ng of total RNA was treated
with RQ1 RNase-free DNase (Promega, Madison,WI, USA) and used for
cDNA synthesis with specific reverse primers. For each sample, a reaction
without reverse transcriptase (RT) was run in parallel to control for
DNA contamination. A quantitative RT-PCR for E7 was performed using
a newly developed quantitativeHPVdetectionmethod, which allowed the
analysis of all HPV types under study, except for HPV70 (A. T. Hesselink,
J. Berkhof, M. L. van der Salm, A. P. van Splunter, T. H. Geelen, F. J. van
Kemenade, M. G. B. Bleeker, and D. A.M. Heideman, unpublished data).
As a reference, we performed a qRT-PCR for snRNP, as described previ-
ously (34).
hTERT expression analysis and telomerase activity. For hTERT
mRNA expression analysis, 500 ng of total RNA was treated with RQ1
RNase-free DNase (Promega), and qRT-PCRwas performed as described
previously (35).
Telomerase activity was measured using the TeloTAGGG Telomerase
PCR ELISAPlus kit (Roche,Mannheim, Germany) according to theman-
ufacturer’s protocol.
Beta-galactosidase staining. Senescent cells were detected by staining
for acidic -galactosidase (36). Cells were fixed in 3% formaldehyde in
phosphate-buffered saline (PBS), washed with PBS, and stained with 40
mM citric acid-sodium phosphate buffer (pH 6), 5 mM potassium ferri-
cyanide, 5 mM potassium ferrocyanide, 150 mM sodium chloride, 2 mM
magnesium chloride, 1 mg/ml X-Gal (5-bromo-4-chloro-3-indolyl--D-
galactopyranoside) at 37°C in the absence of CO2.
Protein extraction and Western blotting. Total cellular protein ex-
tracts were derived from exponentially growing cells as described previ-
ously (37). Fifteen micrograms of protein lysates was electrophoresed on
an SDS-PAGE gel and transferred to a nitrocellulosemembrane. Antibod-
ies anti-p53 (clone D07; Dako, Glostrup, Denmark; 1:1,000), anti-pRb
(clone 4H1; Cell Signaling Technology, Beverly,MA,USA; 1:1,000),-ac-
tin (Cell Signaling Technology; 1:1,000), and anti-p16INK4A (G175-1239;
BD Pharmingen; 1:1,000) were incubated in 3% dry milk in PBS contain-
ing 0.05% Tween 20 at 4°C overnight. For detection, membranes were
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incubated with the appropriate horseradish peroxidase-conjugated sec-
ondary rabbit anti-mouse (p0260; Dako; 1:1,000) and swine anti-rabbit
(p0217;Dako; 1:1,000) antibody for 1 h, and protein levels were visualized
with enhanced chemiluminescence (ECL) (GE Healthcare, Buckingham,
United Kingdom).
Organotypic raft culture system and immunohistochemical stain-
ing. Organotypic raft cultures of untransduced HFKs and HPV E6/E7-
transduced cells were performed as described previously (38). For all cul-
tures, duplicate raft cultures were performed. Briefly,mouse fibroblast (J2
3T3) cells were seeded in a dermal equivalent. The raft culture medium
contained DMEM-Ham’s F-12 (3:1), 10% fetal calf serum (Life Technol-
ogies), hydrocortisone (0.4 g/ml), 0.1 nM cholera toxin, transferrin (5
g/ml), insulin (5g/ml) (all fromSigma), and human epidermal growth
factor (0.5 ng/ml; Life Technologies). The rafts were harvested after 9
days, fixed in 10% saline-buffered formalin, paraffin embedded, and sub-
jected to immunohistochemical staining.
Immunohistochemical staining was performed on 4-m sections,
which were deparaffinized and rehydrated. Following antigen retrieval
with citrate buffer (pH 6; 800W; 10min), the slides were incubated for 30
min in 3% H2O2 in methanol and incubated overnight with MIB/Ki-67
(M7240; Dako; 1:40) and cytokeratin 10 (NCL-CK10; Novo Castra Lab-
oratories; 1:200). For detection, the Envision horseradish peroxidase sys-
tem (Dako) was used. Sections were counterstained with hematoxylin.
RESULTS
Generation of HPV E6/E7-transduced HFKs. To analyze the in
vitro immortalization capacity of the hrHPV types 16, 18, 31, 33,
35, 45, 51, 52, and 59 and the probable hrHPV types 66 and 70,
HFKs were transduced with recombinant retroviruses containing
the E6/E7 open reading frames of the respective HPV types.
HPV16, -18, -31, -33, -35, -45, and -66 were cloned from full-
lengthHPV plasmids, which contained the prototype, as was con-
firmed by sequencing analysis. HPV52 was also amplified from a
full-lengthHPVplasmid and contained a sequence variation in E6
(K93R). This HPV52 variant has frequently been detected in cer-
vical cancers in Asia (39, 40). HPV51 and HPV59 E6/E7 were
cloned from cervical scrapes, and HPV70 was cloned from a
tumor sample. Sequencing analysis revealed nonsilent sequence
variations in HPV51 E7 (S66L), HPV59 E7 (L19G, L20F, and
H95R), and HPV70 E6 (N100D) relative to the GenBank proto-
type sequences (41, 42). LrHPV11 and the empty vector (LZRS)
were included as negative controls. To control for genetic-back-
ground-dependent variations, HFKs isolated from at least two in-
dependent individuals were transduced. Cells isolated from the
first donor, referred to as donor I, were transduced with all con-
structs. Cells from the second donor, donor II, were transduced
with all constructs, except for HPV33, due to technical problems.
Cells from a third donor (donor III) were transduced with
HPV16, -33, -35, -45, -51, -52, -59, and -70.
At various passages throughout culturing, the presence of the
correct HPV type was confirmed by type-specific DNA PCR anal-
ysis (data not shown). Moreover, analysis of viral DNA quantities
in all transductants, using qPCR for the vector backbone, revealed
relatively minor variations between cell lines, which were gener-
ally not donor related and most likely reflect neomycin selection
(data not shown).
p53 and pRb status. To examine whether the E6 and E7 onco-
genes of the different HPV types display different abilities to de-
grade p53 and pRb and to reactivate p16INK4A, we first verified
transgene expression by RT-PCR using HPV type-specific E6 and
E7 primer sets. Both E6 and E7 were expressed in the various
transductants of all three donors (Fig. 1A). Quantitative RT-PCR
analysis for E7 verified comparable levels of viral oncogene expres-
sion between donors (Fig. 1B). Only in the case of HPV35 was a
relatively low level of expression seen in donor I. HPV70 E7 ex-
pression could not be examined using this method.
Western blot results showing p53, pRb, and p16INK4A expres-
sion levels at early passage (passage 8; 30 to 40 population dou-
blings [PDs]) are shown in Fig. 1C. Although some slight varia-
tions between the different donors were evident, (probable)
hrHPV-transduced cells showed generally decreased p53 levels to
various degrees in comparison to untransduced and LZRS- and
HPV11-transduced HFKs. In donor I, the lowest p53 levels were
observed in HPV16, -31, -33, and -59 transductants, similar to
donor III, in which p53 was markedly reduced in HPV16-, -33-,
and -59-transducedHFKs (Fig. 1C). In donor II, less variationwas
evident, and allHPV16-, -18-, -31-, -33-, -45-, -51-, -59-, -66-, and
-70-transduced HFKs showed decreased p53 levels.
pRb protein expression was also decreased to various degrees
in all (probable) hrHPV transductants compared to controls (Fig.
1C). In some cell lines, an inverse correlation was seen between
p53 and pRb degradation. The relatively low E7 expression in
HPV35 transductants from donor I compared to donors II and III
was not linked to reduced pRb degradation. The reduced pRb
expression in donor I cells transduced with HPV11 and untrans-
duced cells fromdonor IImay reflect the onset of senescence in the
cells.
To further validate HPV biological activity, we investigated
p16INK4A protein levels. HrHPVE7 expression induces increased
p16INK4A expression, being either or both pRb-dependent and -in-
dependent (43, 44). p16INK4A protein levels were strongly in-
creased in all (probable) hrHPV-transduced HFKs (Fig. 1C).
Elevated p16INK4A expression was also observed in HPV11 trans-
ductants from donor I and untransduced cells from donor II that
had reduced pRb expression.
Splicing of the HPVE6 mRNA. Next, we aimed to determine
whether variations in p53, pRb, andp16INK4A levels were related to
differences in alternative splicing of the hrHPVE6E7 transcripts in
favor of eithermore full-length E6 template or full-length E7 tem-
plate. RT-PCR was performed on DNase-treated RNA samples
using primers located upstream and downstream of the predicted
donor-acceptor splice sites (Fig. 1D). In accordance with previous
reports (12, 23), only a single band encoding full-length E6/E7was
observed in HPV11-transduced HFKs. The most prominent
product seen in HPV16-, -18-, -31-, -33-, -35-, -45-, -51-, -52-,
and -70-transduced HFKs represented an E6*I splice variant that
was confirmed by sequencing. In HPV16-, -18-, -31-, -59-, and
-66-transduced HFKs also, a full-length E6/E7 transcript was ob-
served, which was most prominent in all HPV59 transductants
and HPV66-transduced cells from donor I. Only in the case of
HPV16 was an E6*II splice variant seen.
The presence of spliced E6*I transcripts in all (probable)
hrHPV-transduced cell lines suggests that the observed variations
in p53 and pRb degradation were not (entirely) due to alternative
splicing of the E6/E7 transcripts.
Cell culture growth characteristics. To determine how the
above-described characteristics correlated with immortalization,
cells were closely monitored during culture for their potential to
bypass the two proliferative life span barriers, i.e., senescence,
which leads to an extended life span, and crisis, resulting in im-
mortalization (Fig. 2A and B).
Based on their culture characteristics, distinct groups could be
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discerned. The first group comprised untransduced and LZRS-
and HPV11-transduced HFKs, which did not overcome senes-
cence. In more detail, untransduced HFKs from donors I, II, and
III entered senescence and eventually died after 38 PDs, 30 PDs,
and 33 PDs, respectively (Fig. 2A and B). Cells transduced with
empty vector (LZRS) senesced and died after 37, 39, and 40 PDs,
respectively, andHPV11-transduced cells died after 43 PDs and 35
PDs for donors I and II, respectively. Morphologically, all un-
transduced HFKs and HFKs transduced with LZRS and HPV11
contained large, flattened cells, a senescence-related phenotype,
upon approaching the last population doublings. Senescence was
confirmed by staining for senescence-associated beta-galactosi-
dase (SA--Gal) (Fig. 2C).
The second group consisted of HFKs transduced with HPV16,
-18, -31, -33, and -35, which showed no signs of senescence or
crisis throughout culturing and proliferated continuously in all
FIG 1 Functional expression of the viral oncogenes E6 and E7 in the various transductants. (A) E6 and E7 mRNA expression assessed by type-specific RT-PCR.
RT-negative PCR (), without reverse transcriptase, served as a negative control, and snRNP expression analysis was included as a housekeeping control. (B)
Relative E7mRNA expression determined by qRT-PCR. HPV51 donor III andHPV70 transductants could not be analyzed. mRNA expression was corrected for
the housekeeping gene snRNP and is shown relative to donor I. (C) Steady-state protein levels of p53, pRb, and p16INK4A in preimmortal HFKs transduced with
empty vector (LZRS) andHPV11, -16, -18, -31, -33, -35, -45, -51, -52, -59, -66, and -70, as determined byWestern blotting.-Actin expression served as a loading
control. (D) E6/E7 mRNA products. Full-length transcripts are indicated by arrowheads, and spliced E6 mRNAs are indicated by asterisks (*, E6*I; **, E6*II).
SnRNP served as a housekeeping control. mRNA and protein products of donor I are shown as representative.
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three donors. Interestingly, these HPV types demonstrated the
highest p53 degradation efficiencies. HPV18-transduced cells,
which showed somewhat less efficient degradation of p53, en-
countered slight growth reduction for 61 days between 54 and 76
PDs in donor I and for 70 days between 58 and 69 PDs in donor II.
During this period, a mixture of senescent cells and proliferating
cells was observed.
HPV45-, -51-, -59-, -66-, and -70-transduced cells comprised
the third group. Although these types revealed an abnormal
growth pattern, their transductants endured a strong and long
crisis period prior to immortalization. In HPV45-transduced
HFKs from donor I, senescent cells were seen after 101 PDs, and
after 189 days of crisis, islands of small proliferating cells emerged.
In donors II and III, crisis was entered at 97 PDs and 60 PDs, and
the cells eventually died. In HPV51-transduced HFKs, senescent-
like cells appeared after 104 PDs, 62 PDs, and 70 PDs in donors I,
II, and III, respectively.Whereas cells started to proliferate after 52
days in donor I, HPV51 transductants of donors II and III even-
tually died. TheHPV59-transducedHFKs revealed senescent cells
at 48 PDs and 72 PDs and escaped crisis after 64 and 202 days in
donor II and donor III, respectively. In donor I, senescence was
entered at 20 PDs, and the cells eventually died. In both HPV66-
transduced donors, a strong crisis period was observed. The crisis
period in donor I started at 53 PDs and ended after 130 days.
Donor II cells transduced with HPV66 entered crisis after 87 PDs,
which lasted 112 days. A similar growth pattern was observed in
HFKs transduced withHPV70. Those from donors I and II ceased
to proliferate after 81 PDs and 78 PDs and escaped crisis after 67
and 94 days, respectively. HPV70-transduced HFKs from donor
III entered crisis at 71 PDs, which lasted longer (255 days) and
from which a single colony of immortal cells emerged. Crisis-like
cells show a senescent morphology, as verified by staining for se-
nescence-associated beta-galactosidase.
The fourth group includes all HPV52-transduced HFKs with
an extended life span that was followed by a long crisis period and
eventual cell death. HPV52-transduced HFKs from donors I and
II entered a strong crisis period after 62 PDs and 81 PDs, respec-
tively. HPV52-transduced cells from donor III entered senescence
after 32 PDs, and none of the HPV52-transduced HFKs bypassed
crisis. Even upon repeated thawing and culturing of early-passage
transductants, no outgrowth of immortal cells was seen.
Immortalization.To find support for the fact that all HPV16-,
-31-, -33-, -35-, -66-, and -70-transduced HFKs, as well as one
donor’s HPV45- and -51- and two donor’s HPV59-transduced
HFKs that escaped from crisis, were indeed immortal, hTERT
mRNA expression and telomerase activation were analyzed (Fig.
3). qRT-PCR analysis revealed no hTERT expression in untrans-
ducedHFKs andHFKs transducedwith LZRS andHPV11. In cells
without an intervening crisis period (HPV16-, -31-, and -33-
transduced cells), but also HPV59-transduced cells (with a crisis
period), generally low levels of hTERT mRNA were detected at
early passage (44 PDs). These levels progressively increased at 62
to 137 and150 PDs, respectively. In other transductants with an
intervening crisis period (with the exception of HPV52-trans-
duced cells from donor I), i.e., HPV45, -51, -52, -66, and -70, as
well asHPV18, transductants, no hTERT expressionwas observed
at early passage (44 PDs). hTERT expression, however, became
apparent as soon as proliferating cells escaped from crisis (de-
pending on the donor, 70 to 100 PDs) andwas increased further at
150 PDs.
All immortalized cell cultures showing elevated hTERTmRNA
expression tested positive for telomerase activation (Fig. 3, bot-
tom). Weak telomerase activity was seen in early-passage cells
from HPV51 donors II and III, HPV52 donor III, and HPV59
donor I, all of which did not become immortal.
Raft culturesof the transductantsdisplaydysplastic changes.
Since immortalization of HFKs by full-length HPV16 andHPV18
has previously been associated with disturbed differentiation in
organotypic raft cultures (38), the differentiation capacities of
HPV16, -18, -31, -33, -35, -45, -59, -66, and -70 transductants
were assessed at approximately equal passages (90 to 161 PDs)
(Fig. 4). Raft cultures of untransduced HFKs closely resembled
normal epithelium, showing distinct basal/parabasal, spinous,
granular, and cornified layers. Immunohistochemical staining for
Ki-67 revealed that proliferating cells were restricted to the basal/
parabasal layer of the epithelium. The spinous and granular layers
of the untransduced cells stained positive for the differentiation
marker cytokeratin 10 (CK10).
Organotypic raft cultures ofHPV16 (PD 104), -18 (PD 90), -31
(PD 103), -35 (PD 140), and -66 (PD 97) containing HFKs from
donor I; HPV16 (PD 132), -31 (PD 101), -35 (PD 147), -59 (PD
92), -66 (PD 106), and -70 (PD 103) containingHFKs fromdonor
II; andHPV16 (PD 117), -33 (PD 112), and -35 (PD 161) contain-
ing HFKs from donor III revealed disturbed differentiation, and
no clearly distinct epithelial layers were seen, which was reminis-
cent of severe dysplasia.OnlyHPV33 (PD108)-, -45 (PD90)-, and
-70 (PD 97)-transduced cells from donor I; HPV18 (PD 105)-
transduced cells from donor II; and HPV59 (PD 93)-transduced
cells from donor III showed abnormal differentiation resembling
mild dysplasia. The dysplastic histology of all hrHPV-transduced
cells was characterized by the presence of basal-like cells in almost
all strata of the epithelium, as indicated by the presence of Ki-67-
positive cells in upper cell layers and the absence of CK10 staining.
Only theHPV70 (PD 97) transductant of donor I, theHPV18 (PD
105) and -35 (PD 147) transductants of donor II, and the HPV35
(PD 161) and -59 (PD 93) transductants of donor III stained
(weakly) positive forCK10.Unfortunately, theHPV70-immortal-
ized HFKs from donor III repeatedly failed to grow on organo-
typic rafts.
DISCUSSION
In the present study, we systematically compared the viral onco-
genic E6/E7 regions of 9 hrHPV types (HPV16, -18, -31, -33, -35,
-45, -51, -52, and -59) and 2 probable hrHPV types (HPV66 and
FIG 2 Growth characteristics of HPV-transduced HFKs and controls. HFKs were derived from independent individuals and are depicted in red (donor I), blue
(donor II), and green (donor III). (A)HFKs andHFKs transducedwith empty vector (LZRS) andHPV11 entered senescence and died.HPV52-transducedHFKs
had an extended life span and died. A crisis period with reduced growth was observed in HPV45-, -51-, -59-, -66-, and -70-transduced cells prior to immortal-
ization. HPV16-, -18-, -31-, -33-, and -35-transduced HFKs grew continuously in culture. (B) Maximal numbers of population doublings per individual
transductant. The arrows pointing up indicate continuous growth. (C) Representative photographs of HPV-transduced cells and controls (donor I) stained for
senescence-associated-galactosidase.Over 90%of primary cells and cells transducedwith LZRS andHPV11 stained blue.Only single hrHPVE6/E7-transduced
keratinocytes stained blue. The same magnification (	10) was used for all photomicrographs.
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-70) for their effects on knownE6 andE7 targets, such as p53, pRb,
p16INK4A, and hTERT (17), as well as their immortalization capac-
ities. Almost all (probable) hrHPV types, with the exception of
HPV52 (alpha 9), were able to induce immortalization of HFKs,
albeit with different efficiencies, as schematically represented in
Fig. 5. E6/E7 of the closely related types HPV16, -31, -33, and -35
of the alpha 9 genus and, to a lesser extent, HPV18 (alpha 7 genus)
displayed the highest growth-promoting activities early during the
transformation process, with no signs of senescence or crisis
throughout culture. This was generally accompanied by promi-
nent E6 activity exemplified by relatively low p53 levels compared
to other types and early onset of hTERT expression. HFKs trans-
duced with HPV45, -59, and -70 (alpha 7); HPV51 (alpha 5); and
HPV66 (alpha 6) encountered a long crisis period prior to immor-
talization. These types, with the exception of HPV59, showed no
hTERT expression in preimmortal transductants. Growth charac-
teristics were not related to the relatively small differences seen in
transgene DNA copy numbers and expression levels. Overall, our
Western blot results are in line with earlier reports showing p53
and pRb degradation by (probable) hrHPV types, but not by
HPV11 (11–13, 45). Similar to other in vitro studies (11, 12), the
p53 degradation capacities varied among the hrHPV types. How-
ever, type differences are not fully consistent across the different
studies, most likely reflecting the different model systems and as-
says used. In a comparative study by Hiller et al. (11) using in
vitro-translated E6, almost equal degradation efficiencies of p53
were found for HPV16, -18, -33, -35, -39, -45, -51, -52, -53, -56,
-58, -66, -70, and -82. Using a more quantitative approach,
HPV58 and -59 E6 proteins were found to be the most potent
types, and HPV56 and -66 showed the least p53 degradation ac-
tivity (12). HPV16, -18, -31, -33, and -35 had slightly lower p53
degradation capability than HPV45, -51, -52, -59, and -70 (12).
The discrepancies with the present study may, at least in part, be
explained by E6 being expressed from a bicistronic E6/E7 mRNA,
which is subject to alternative splicing, potentially affecting E6
activity. HPV18 E6*I has been demonstrated to counteract full-
length E6 in p53 degradation (30). In the study by Mesplede et al.
(12) using HPV E6-transfected cells, splicing was observed in
HPV16, -18, -31, -33, -35, -51, -66, and -70 E6-, but not inHPV45,
-52, and -59 E6-transfected cells. In all our (probable) hrHPV-
transduced cell lines, E6*I expression was detected. Full-length E6
wasmost prominent in HPV66 from donor I and all three HPV59
transductants, whichwas associatedwithmore p53 degradation in
HPV59-, but not in HPV66-transduced HFKs. These data suggest
that differences in alternative splicing do not fully account for the
variations in p53/pRb degradation and immortalization capaci-
ties. The latter most likely depend on potential type-dependent
interactions with other cellular targets, as well (46).
E6-mediated activation of telomerase via hTERT promoter ac-
tivation, as originally demonstrated for HPV16 (47–49), has re-
cently also been demonstrated for other HPV types using lucifer-
ase assays and was found to be HPV type dependent.With respect
FIG 3 (Top) Relative hTERTmRNA expression levels as determined by quantitative reverse transcriptase PCR in cells at a preimmortal stage (16 to 44 PDs), at
62 to 116 PDs (precrisis in the case ofHPV45 and postcrisis in the cases ofHPV51, -66, and -70 transductants), and at an immortal stage (157 to 301 PDs). Shown
is a representative experiment performed in duplicate on donor I. The error bars indicate standard deviations. (Bottom) Telomerase activity as determined using
the TeloTAGGG Telomerase PCR ELISAPlus kit (Roche, Mannheim, Germany). 
, telomerase positive; 
/, weakly telomerase positive; , telomerase
negative; NA, not applicable.
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to the types studied by us, HPV16, -33, -35, -51, and -52 E6 pro-
teins showed the highest hTERT promoter activation capacities,
followed by HPV18 and -31. HPV11, -66, and -70 E6 proteins
displayed no elevated hTERT activation, andHPV45 and -59were
not tested (50). In our study, hTERT expression was primarily
found to be directly upregulated, albeit still at a relatively low level,
in cell lines in which no intervening crisis period was observed,
i.e., upon HPV16, -31, -33, or -35 transduction, as well as upon
HPV59 transduction. This implies that upon stable transduction
and in the presence of naturally occurring splice products, the E6
proteins of HPV16, -31, -33, -35, and -59 can induce low levels of
hTERT transcription themselves, whereas the E6 proteins of
HPV45, -51, -52, -66, and -70 may lack this ability. The major
discrepancy between our results and the study by Van Doorslaer
and Burk (50) concerns HPV51 and -52, which may be related to
E6*I expression being dominant in the present study. The fact that
in all cell lines hTERT expression levels increased upon passaging
indicates that, besides HPV, additional events contribute to telo-
merase activation and immortalization, in line with previous ob-
servations (51–53). Recent studies indicate that telomerase-inde-
pendent functions of hTERT also contribute to HPV-induced
immortalization of HFKs; among others, they involve bypass of
senescence by regulation of a gene set similar to that regulated by
hrHPV E6 (54). How the increasing hTERT expression levels with
passaging correlate with its telomeric and nontelomeric functions
is currently unclear.
Whereas HPV16, -18, -31, -33, and -35 induced immortaliza-
tion in all donors, immortalization by HPV45 was infrequent.
Although this observation was surprising given its relatively high
prevalence in cervical cancer worldwide (7), one may speculate
thatHPV45 ismore effective in the induction of subsequent trans-
formation events, such as anchorage-independent growth and
colony formation, as was shown for HPV18 compared to HPV16
(55).
Infrequent induction of immortalization by HPV51, on the
other hand, is in line with epidemiological data showing a strong
decrease in prevalence with the progression of cervical disease
(56).
HPV52 invariably induced an extended life span but failed to
FIG 4 Organotypic raft cultures of untransduced and HPV16-, -18-, -31-,
-33-, -35-, -45-, -66-, and -70-transduced HFKs. (A) H&E (hematoxylin and
eosin) staining showing raft culture morphology. (B and C) Immunohisto-
chemical staining on sections of the same cultures as in panel A were per-
formed for the proliferation marker Ki-67 (B) and the differentiation marker
CK10 (C). Raft cultures were performed in duplicate, and one raft per HPV
type from donor I is shown as representative.
FIG5 Schematic representation of the immortalization characteristics of untransduced and empty-vector (LZRS)- andHPV11-, -16-, -18-, -31-, -33-, -45-, -51-,
-52-, -59-, -66-, and -70-transducedHFKs. Control transductants (HFKs, LZRS, andHPV11)were unable to degrade p53, showed no hTERT expression, entered
senescence (M1), and died. Immortalization of HFKs transduced with HPV16, -31, -33, and -35 and, to a lesser extent, HPV18 was reached without an
intervening crisis period (M2).Those cells generally showed strong p53 degradation and early onset of hTERT expression. HPV45-, -51-, -59-, -66-, and
-70-transduced HFKs became immortal following a strong crisis period and, with the exception of HPV59, generally showed less efficient p53 degradation.
hTERT expression was evident following escape from crisis. HPV52-transduced cells without obvious p53 degradation remained hTERT negative and had an
extended life span but failed to induce immortalization.
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induce immortality. The E6 K93R variant in our construct is pres-
ent in 98% of the HPV52-positive cervical cancers in Japan (39,
40, 56) and has been significantly associated with an increased
CIN2/3 risk, suggesting that it represents a carcinogenic variant
(57), yet the findings that p53 expression levels were unaltered and
immortalization was unsuccessful in our hands indicate that this
highly common variant is not as oncogenic as other hrHPV types,
at least in a Caucasian genetic background.
HPV59, which is less prevalent in invasive cervical cancers (7),
showed a better immortalization capacity. Despite three sequence
variants in E7, the observed pRb degradation and p16INK4A up-
regulation indicates E7 activity.We cannot rule out the possibility
that these variants render HPV59 more carcinogenic, as was
shown for the Asian-American HPV16 E6 variant AAE6 (amino
acid changes Q14H/H78Y/L83V) compared to the prototype
(58, 59).
All donors transducedwith hrHPV66 andHPV70 encountered
a long crisis period, followed by the escape of single colonies of
telomerase-positive cells. These findings are in accordance with
earlier studies showing successful immortalization of primary
keratinocytes by full-lengthHPV66 andHPV70E6/E7 (11, 14). This
study, however, is the first to systematically demonstrate that these
probable hrHPV types display a reduced immortalization capacity
compared to the established hrHPV types 16, 18, 31, 33, and 35.
Unfortunately, no proper comparison to the various published
studies can be made, given the fact that, besides varying culture
conditions,most studies lack a comparative analysis betweenmul-
tiple HPV types and/or used a single keratinocyte isolate.
The reduced immortalization capacity of the hrHPV types 45,
51, 52, and 59 and the probable hrHPV types 66 and 70may in part
explain their rare detection in CIN3 lesions (15, 18), though the
overall prevalence and potentially more efficient clearance by the
immune system can also be important determinants. Diverse
mechanisms of interference with immune surveillance and im-
mune escape ofHPV-induced lesions have been described, such as
interference with interferon response, downregulation of major
histocompatibility complex (MHC) class I and TAP-1, and con-
trol of Langerhans cell density (60–62). However, the potential
existence of type-dependent mechanisms of immune escape and
the role of the tumor microenvironment are still largely unex-
plored. Furthermore, we cannot rule out the possibility that the
oncogenicity of HPV45, -51, -52, and -59 is epithelium depen-
dent, although no such cell type dependency was demonstrated
for HPV11, -16, -18, and -31 (55).
The finding that HPV16, -18, -31, -33, and -35 displayed the
highest immortalization efficiency in a donor-independent man-
ner corresponds to epidemiological studies in which HPV16, -18,
-31, and -33 revealed the highest 18-month risk of developing into
CIN3 or higher lesions and an increased prevalence in cervical
cancers (7, 8, 56). The reduced immortalization efficiency of other
types, like HPV45, -51, -52, -59, -66, and -70, reflected by a long
crisis period and donor-dependent outgrowth of immortal cells,
underlines the value of comparative analysis in multiple donors.
Most studies so far have made use of a single HFK donor.
Shortly after immortalization, all hrHPV-transduced keratino-
cytes showed disturbed differentiation on organotypic raft cul-
tures, and most were histologically classified as severe dysplasia,
reminiscent of high-grade CIN, indicating that histomorphology
is type independent, whereas molecular phenotypes may be type
dependent (63).
These in vitromodels not only enable a systematic comparison
of the immortalization and transformation capacities of (proba-
ble) hrHPV types, but will also aid our understanding of the type-
dependent molecular mechanisms of transformation.
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